Advertisement

Her-2/neu Transgenic Mice for Evaluation of Immune and Antitumor Responses Against Self-Tumor Antigens in the Young and the Old

  • Joseph Lustgarten
  • Noweeda Mirza

Abstract

The impact of aging on T-cell tolerance has yet to be elucidated. More importantly cancer vaccines that will be effective both in the young and the old have yet to be developed. As a result, there is a need for relevant tumor models which include aspects of self-tolerance and development of spontaneous tumors in the aged. Such models are critical for the development and optimization of specific cancerrelated immunotherapeutic strategies for the elderly. Although the majority of studies augmenting immune responses against a self-antigen like the Her-2/neu have used young Her-2/neu transgenic mouse models and put a lot of effort into aspects such as increasing the immunogenicity, very little attention has been paid to the immune competence of the aging population. Based on the Her-2/neu transgenic mice, our group has developed a mouse model (HLA-A2.1/Kb mice crossed with the FVBHer- 2/neu mice) where self-tolerance, spontaneous tumor progression and aging are present simultaneously. The immunological aspects of the A2xneu mice closely reflect those of cancer patients whose immune systems are not fully competent to reject their tumors. Models like this are critical as they may provide data that closely predict the clinical outcomes and will help to customize immunotherapeutic strategies that would be effective for the treatment of tumors in both the young and the old. In this chapter, we will focus on the Her-2/neu transgenic mouse model for the evaluation of immune and antitumor responses against a self-tumor antigen in both the young and the old.

Keywords

Antitumor Immune Response Antitumor Response Immunotherapeutic Strategy Heteroclitic Peptide Heat Shock Protein Heat Shock 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Akiyama T et al (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646PubMedCrossRefGoogle Scholar
  2. 2.
    Ambrosino E et al (2006) Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 66:7734–7740PubMedCrossRefGoogle Scholar
  3. 3.
    Amici A et al (2000) DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 7:703–706PubMedCrossRefGoogle Scholar
  4. 4.
    Babatz J et al (2006) Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 55(3):268–276PubMedCrossRefGoogle Scholar
  5. 5.
    Banchereau J, Steinman R (1998) Dendritic cells and the control of immunity. Nature 392:245–252PubMedCrossRefGoogle Scholar
  6. 6.
    Banchereau J et al (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811PubMedCrossRefGoogle Scholar
  7. 7.
    Bargmann CM, Hung Weinberg R (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649PubMedCrossRefGoogle Scholar
  8. 8.
    Barton G, Medzhitov R (2002) Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 14:380–383PubMedCrossRefGoogle Scholar
  9. 9.
    Binder R (2006) Heat shock protein vaccines: from bench to bedside. Int Rev Immunol 25:353–375PubMedCrossRefGoogle Scholar
  10. 10.
    Bloom E et al (1990) Age-related decrement in cytotoxic T lymphocyte (CTL) activity is associated with decreased levels of mRNA encoded by two CTL-associated serine esterase genes and the perforin gene in mice. Eur J Immunol 20:2309PubMedCrossRefGoogle Scholar
  11. 11.
    Boggio K et al (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589–596PubMedCrossRefGoogle Scholar
  12. 12.
    Boggio K et al (2000) Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60(2):359–364PubMedGoogle Scholar
  13. 13.
    Borras E et al (2002) Findings on T cell specificity revealed by synthetic combinatorial libraries. J Immunol Methods 267:79PubMedCrossRefGoogle Scholar
  14. 14.
    Brennan P et al (2003) Anergy and suppression as coexistent mechanisms for the maintenance of peripheral T cell tolerance. Immunol Res 27:295–302PubMedCrossRefGoogle Scholar
  15. 15.
    Brossart P et al (1998) Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732PubMedGoogle Scholar
  16. 16.
    Cappello P et al (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 63:2518–2525PubMedGoogle Scholar
  17. 17.
    Caruthers S, Wickline S, Lanza G (2007) Nanotechnological applications in medicine. Curr Opin Biotechnol 18:26–30PubMedCrossRefGoogle Scholar
  18. 18.
    Chan T et al (2006) HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 13(19):1391–1402PubMedCrossRefGoogle Scholar
  19. 19.
    Chen Y et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914PubMedCrossRefGoogle Scholar
  20. 20.
    Chen Y et al (1998) DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 58:1965–1971PubMedGoogle Scholar
  21. 21.
    Chong G, Morse M (2005) Combining cancer vaccines with chemotherapy. Expert Opin Pharmacother 6:2813–2820PubMedCrossRefGoogle Scholar
  22. 22.
    Chouaib S et al (1997) The host-tumor immune conflict: from immuosuppression to resistance and destruction. Immunol Today 18(10):493–497PubMedCrossRefGoogle Scholar
  23. 23.
    Cifaldi L et al (2001) A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 61:2809–2812PubMedGoogle Scholar
  24. 24.
    Copier J, Dalgleish A (2006) Overview of tumor cell-based vaccines. Int Rev Immunol 25:297–319PubMedCrossRefGoogle Scholar
  25. 25.
    Cordaro T et al (2002) Can low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol 168:651–660PubMedGoogle Scholar
  26. 26.
    Cordaro T et al (2002) Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol 168:651PubMedGoogle Scholar
  27. 27.
    Coussens L et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230(4730):1132–1139PubMedCrossRefGoogle Scholar
  28. 28.
    Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3(8):609–620PubMedCrossRefGoogle Scholar
  29. 29.
    Cuadros C et al (2003) Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. Cancer Res 63(18):5895–5901PubMedGoogle Scholar
  30. 30.
    Cuadros C et al (2005) Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 116(6):934–943PubMedCrossRefGoogle Scholar
  31. 31.
    Daudel DG, Weidinger, Spreng S (2007) Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 6:97–110PubMedCrossRefGoogle Scholar
  32. 32.
    De Giovanni, C et al (2004) Immunoprevention of HER-2/neu trangenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 64:4001–4009PubMedCrossRefGoogle Scholar
  33. 33.
    de Visser K et al (2000) Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur J Immunol 30:1458–1468PubMedCrossRefGoogle Scholar
  34. 34.
    de Visser K et al (2001) Low-avidity self-specifiic T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J Immunol 167:3818PubMedGoogle Scholar
  35. 35.
    Di Carlo E et al (1999) Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 79(10):1261–1269PubMedGoogle Scholar
  36. 36.
    Di Carlo E et al (2001) Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clinc Cancer Res 7(3 Suppl):830s–837sGoogle Scholar
  37. 37.
    Disis M et al (2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Tre at 62:245–252CrossRefGoogle Scholar
  38. 38.
    Disis M et al (2004) Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24(5):571–578PubMedCrossRefGoogle Scholar
  39. 39.
    El-Shami K et al (2000) Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. Int J Cancer 85:236PubMedGoogle Scholar
  40. 40.
    Ercolini A et al (2003) Identification and characterization of the immunodominant rat HER-2/ neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 170(8):4273–4280PubMedGoogle Scholar
  41. 41.
    Ercolini A et al (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591–1602PubMedCrossRefGoogle Scholar
  42. 42.
    Feltkamp M et al (1993) Vaccination with cytotoxic T lymphocyte epitope- containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242PubMedCrossRefGoogle Scholar
  43. 43.
    Frederick B et al (2006) ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 64:33–37PubMedGoogle Scholar
  44. 44.
    Gallo P et al (2005) Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113:67–77PubMedCrossRefGoogle Scholar
  45. 45.
    Gallo P et al (2007) Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int J Cancer 120:574–584PubMedCrossRefGoogle Scholar
  46. 46.
    Garnett C et al (2006) TRICOM vector based cancer vaccines. Curr Pharm Des 12:351–361PubMedCrossRefGoogle Scholar
  47. 47.
    Geiger TL, Gooding, Flavell R (1992) T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci U S A 89:2985–2989PubMedCrossRefGoogle Scholar
  48. 48.
    Goldrath A, Bevan M (1999) Selecting and maintaining a diverse T-cell repertoire. Nature 402:255–262PubMedCrossRefGoogle Scholar
  49. 49.
    Gramaglia I et al (1998) Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161:6510PubMedGoogle Scholar
  50. 50.
    Gresser I, Belardelli F (2002) Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 13:111–118PubMedCrossRefGoogle Scholar
  51. 51.
    Guinn B et al (1999) 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 162:5003PubMedGoogle Scholar
  52. 52.
    Gusterson B et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10(7):1049–1056PubMedGoogle Scholar
  53. 53.
    Guy C et al (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578PubMedCrossRefGoogle Scholar
  54. 54.
    Hanahan D, Folkman J (1996) Pattern and emerging mechanism of the angiogenic switch during tumorgenesis. Cell 86:353PubMedCrossRefGoogle Scholar
  55. 55.
    Harrop R, Carroll M (2006) Viral vectors for cancer immunotherapy. Front Biosci 11:804–817PubMedCrossRefGoogle Scholar
  56. 56.
    Harrop RJ, John, Carroll M (2006) Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 58:931–947PubMedCrossRefGoogle Scholar
  57. 57.
    Hausmann S et al (1999) Structural features of autoreactive TCRthat determine the degree of degeneracy in peptide recognition. J Immunol 162:338PubMedGoogle Scholar
  58. 58.
    Hausmann S et al (1999) Structural features of autoreactive TCRthat determine the degree of degeneracy in peptide recognition. J Immunol 162:338–344PubMedGoogle Scholar
  59. 59.
    He Y et al (2005) Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174(6):3808–3817PubMedGoogle Scholar
  60. 60.
    Heath A, Playfair J (1992) Cytokines as immunological adjuvants. Vaccine 10:427–434PubMedCrossRefGoogle Scholar
  61. 61.
    Hemmer B et al (1999) Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med 5:1375PubMedCrossRefGoogle Scholar
  62. 62.
    Herbst R, O’Reilly M (2003) The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Semin Oncol 30:113–123PubMedCrossRefGoogle Scholar
  63. 63.
    Holmgren L et al (2006) A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A 103:9208–9213PubMedCrossRefGoogle Scholar
  64. 64.
    Houbiers J et al (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072PubMedCrossRefGoogle Scholar
  65. 65.
    Houghten R et al (1991) Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 354:84PubMedCrossRefGoogle Scholar
  66. 66.
    Houghten R et al (1999) Mixture-based synthetic combinatorial libraries. J Med Chem 42:3743PubMedCrossRefGoogle Scholar
  67. 67.
    Hudis C (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39–51PubMedCrossRefGoogle Scholar
  68. 68.
    Hussain M et al (2007) Trastuzumab, Paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218–2224PubMedCrossRefGoogle Scholar
  69. 69.
    Ioannides C et al (1993) Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 151:225PubMedCrossRefGoogle Scholar
  70. 70.
    Jackson-Grusby L (2002) Modeling cancer in mice. Oncogene 21(35):5504–5514PubMedCrossRefGoogle Scholar
  71. 71.
    Jacobsen M et al (2001) New approaches to dissect degeneracy and specificity in T cell antigen recognition. J Mol Med 79:358PubMedCrossRefGoogle Scholar
  72. 72.
    Janetzki S et al (2000) Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88:232–238PubMedCrossRefGoogle Scholar
  73. 73.
    Kaisho T, Akira S (2002) Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589:1–13PubMedCrossRefGoogle Scholar
  74. 74.
    Kappler J, Roehm N, Marrack P (1987) T cell tolerance by clonal elimination in the thymus. Cell 49:273–280PubMedCrossRefGoogle Scholar
  75. 75.
    Kawai K, Ohashi P (1995) Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 374:68–69PubMedCrossRefGoogle Scholar
  76. 76.
    Kawai K, and Ohashi P (1995) Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 374:68PubMedCrossRefGoogle Scholar
  77. 77.
    Kawakami Y et al (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515PubMedCrossRefGoogle Scholar
  78. 78.
    Kawasaki E, Player A (2005) Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 1(101–109)Google Scholar
  79. 79.
    Kersh G, Allen P (1996) Essential flexibility in the T-cell recognition of antigen. Nature 380:495PubMedCrossRefGoogle Scholar
  80. 80.
    Kim J et al (2001) Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 61:2031PubMedGoogle Scholar
  81. 81.
    Kisielow P et al (1988) Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 333:742–746PubMedCrossRefGoogle Scholar
  82. 82.
    Koido S et al (2005) Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clinc Cancer Res 11(21):7891–7900CrossRefGoogle Scholar
  83. 83.
    Kowalczyk D, Wysocki P, Mackiewicz A (2003) Cancer immunotherapy using cells modified with cytokine genes. Acta Biochim Pol 50:613–624PubMedGoogle Scholar
  84. 84.
    Kunitomi A et al (2002) OX40 signaling renders adult T-cell leukemia cells resistant to Fasinduced apoptosis. Int J Hematol 76:260PubMedCrossRefGoogle Scholar
  85. 85.
    Laderach D et al (2002) 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol 14:1155PubMedCrossRefGoogle Scholar
  86. 86.
    Lenschow D, Walunas T, Bluestone J (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233PubMedCrossRefGoogle Scholar
  87. 87.
    Ligibel L, Winder E (2002) Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 29:38–43PubMedGoogle Scholar
  88. 88.
    Liu M, Wahren B, Karlsson G Hedestam, DNA vaccines: recent developments and future possibilities. Hum Gene Ther 17:1051–1061Google Scholar
  89. 89.
    Lollini P, Forni G (2002) Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 51:409–416PubMedCrossRefGoogle Scholar
  90. 90.
    Lurquin C et al (1989) Structure of the gene of tumtransplantation antigen P91A: the mutated exon encodes a peptide recognized with ld by cytolytic T cells. Cell 58:293PubMedCrossRefGoogle Scholar
  91. 91.
    Lustgarten J et al (1997) Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol 52:109PubMedCrossRefGoogle Scholar
  92. 92.
    Lustgarten J, Dominguez A, Cuadros C (2004) The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 34(3):752–761PubMedCrossRefGoogle Scholar
  93. 93.
    Lustgarten J, Dominguez A, Thoman M (2004) Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 173:4510–4515PubMedGoogle Scholar
  94. 94.
    Lustgarten J, Dominguez A, Pinilla C (2006) Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope. J Immunol 176(3):1796–1805PubMedGoogle Scholar
  95. 95.
    Machiels J et al (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689–3697PubMedGoogle Scholar
  96. 96.
    Manjili M et al (2003) HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171:4054–4061PubMedGoogle Scholar
  97. 97.
    Mason D (1998) A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19:395PubMedCrossRefGoogle Scholar
  98. 98.
    Means T, Golenbock D, Fenton M (2000) Structure and function of Toll-like receptor proteins. Life Sci 68:241–258PubMedCrossRefGoogle Scholar
  99. 99.
    Melani C et al (2003) Myeloid cell explansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102:2138–2145PubMedCrossRefGoogle Scholar
  100. 100.
    Mellman I, Steinman R (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106(3):255–258PubMedCrossRefGoogle Scholar
  101. 101.
    Morgan D et al (1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160:643–651PubMedGoogle Scholar
  102. 102.
    Muller W, et al (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105PubMedCrossRefGoogle Scholar
  103. 103.
    Munz C, Steinman R, Fujii S (2005) Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 202:203–207PubMedCrossRefGoogle Scholar
  104. 104.
    Murata S et al (2006) OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 176(2):974–983PubMedGoogle Scholar
  105. 105.
    Nademanee A et al (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896–2902PubMedCrossRefGoogle Scholar
  106. 106.
    Nagy P et al (1999) Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 5(4):255–271PubMedCrossRefGoogle Scholar
  107. 107.
    Nair, R et al (2006) IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother 29:10–20PubMedCrossRefGoogle Scholar
  108. 108.
    Nair R et al (2006) Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J Immunol 176:7325–7334PubMedGoogle Scholar
  109. 109.
    Nanni P et al (2001) Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194:1195–1205PubMedCrossRefGoogle Scholar
  110. 110.
    Nanni P et al (2003) Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer 105:384–389PubMedCrossRefGoogle Scholar
  111. 111.
    Nava-Parada P et al (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67(3):1326–1334PubMedCrossRefGoogle Scholar
  112. 112.
    Normanno N et al (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65–72PubMedCrossRefGoogle Scholar
  113. 113.
    Offringa R et al (2000) p53: a potential target antigen for immunotherapy of cancer. Ann NY Acad Sci 910:223PubMedCrossRefGoogle Scholar
  114. 114.
    Onizuka S et al (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128–3133PubMedGoogle Scholar
  115. 115.
    Ostrand-Rosenberg S (2004) Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 16:143–150PubMedCrossRefGoogle Scholar
  116. 116.
    Pan P et al (2002) OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther 6:528PubMedCrossRefGoogle Scholar
  117. 117.
    Pannellini T, Forni G, Musiani P (2004) Immunobiology her-2/neu transgenic mice. Breast Dis 20:33–42PubMedGoogle Scholar
  118. 118.
    Pannellini T et al (2006) Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol 176:7695–7703PubMedGoogle Scholar
  119. 119.
    Park J et al (2005) Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 174:4228–4236PubMedGoogle Scholar
  120. 120.
    Pero S et al (2007) Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br J Cancer 96:1520PubMedCrossRefGoogle Scholar
  121. 121.
    Piechocki M, Pilon S, Wei W (2001) Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 167:3367–3374PubMedGoogle Scholar
  122. 122.
    Pinilla C et al (1999) Exploring immunological specificity using synthetic peptide combinatorial libraries. Curr Opin Immunol 11:193PubMedCrossRefGoogle Scholar
  123. 123.
    Pinilla C et al (2001) Combinatorial peptide libraries as an alternative approach to the identification of ligrands for tumor-reactive cytolytic T lymphocytes. Cancer Res 61:5153PubMedGoogle Scholar
  124. 124.
    Pittet M et al (2001) Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol 1:1235PubMedCrossRefGoogle Scholar
  125. 125.
    Plosker G, Keam S (2006) Trastuzumab: a review of its use in the management of HER2- positive metastatic and early-stage breast cancer. Drugs 66:449–475PubMedCrossRefGoogle Scholar
  126. 126.
    Prenzel N et al (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. EdoCRRelat Cancer 8:11–31Google Scholar
  127. 127.
    Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624–632PubMedCrossRefGoogle Scholar
  128. 128.
    Pupa S et al (2001) Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 8:75–79PubMedCrossRefGoogle Scholar
  129. 129.
    Pupa S et al (2005) Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65:1071–1078PubMedGoogle Scholar
  130. 130.
    Quaglino E et al (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 64:2858–2864PubMedCrossRefGoogle Scholar
  131. 131.
    Rabinovich G, Gabrilovich D, Sotomayor E (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296PubMedCrossRefGoogle Scholar
  132. 132.
    Redmond W, Sherman L (2005) Peripheral tolerance of CD8 T lymphocytes. Immunity 22:275–284PubMedCrossRefGoogle Scholar
  133. 133.
    Reilly R et al (2000) HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 60:3569–3576PubMedGoogle Scholar
  134. 134.
    Reilly R et al (2001) The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61:880–883PubMedGoogle Scholar
  135. 135.
    Revillion F, Bonneterre J, Peyrat J (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791PubMedCrossRefGoogle Scholar
  136. 136.
    Rose-John S et al (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80:227–236PubMedCrossRefGoogle Scholar
  137. 137.
    Rosenberg S (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281PubMedCrossRefGoogle Scholar
  138. 138.
    Ross J, Fletcher J (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413PubMedCrossRefGoogle Scholar
  139. 139.
    Rovero S et al (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133–5142PubMedGoogle Scholar
  140. 140.
    Rovero S et al (2001) Insertion of the DNA for the 163–171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther 8:447–452PubMedCrossRefGoogle Scholar
  141. 141.
    Sakaguchi S, Sakaguchi N (2005) Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 24:211–226PubMedCrossRefGoogle Scholar
  142. 142.
    Sakai Y et al (2004) Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 64(21):8022–8028PubMedCrossRefGoogle Scholar
  143. 143.
    Salgaller M et al (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749PubMedGoogle Scholar
  144. 144.
    Santin A et al (1999) Induction of human papillomavirus-specific CD4(+) and CD8 (+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73(7):5402–5410PubMedGoogle Scholar
  145. 145.
    Schwaninger R et al (2004) Virosomes as new carrier system for cancer vaccines. Cancer Immunol Immunother 53:1005–1017PubMedCrossRefGoogle Scholar
  146. 146.
    Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16:53–65PubMedCrossRefGoogle Scholar
  147. 147.
    Sfondrini L et al (2002) Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 16:1749–1754PubMedCrossRefGoogle Scholar
  148. 148.
    Sha W et al (1988) Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature, 335:271–274PubMedCrossRefGoogle Scholar
  149. 149.
    Sharma S, Dominguez A, Lustgarten J (2006) Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4- 1BB. Exp Gerontol 41:78–84PubMedCrossRefGoogle Scholar
  150. 150.
    Sharma S, Dominguez A, Lustgarten J (2006) High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol 177:8348–8355PubMedGoogle Scholar
  151. 151.
    Shuford W et al (1997) R-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186:47PubMedCrossRefGoogle Scholar
  152. 152.
    Singh R et al (2005) Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol 175:3663–3673PubMedGoogle Scholar
  153. 153.
    Singh R, Paterson Y (2006) Vaccination strategy determines the emergence and dominance of CD8 +T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res 66(15):7748–7757PubMedCrossRefGoogle Scholar
  154. 154.
    Singh R, Paterson Y (2007) In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes- based vaccines. Cancer Immunol Immunother 56:927–938PubMedCrossRefGoogle Scholar
  155. 155.
    Singh R, Paterson Y (2007) Immunoediting sculpts tumor eptiopes during immunotherapy. Cancer Res 67:1887–1892PubMedCrossRefGoogle Scholar
  156. 156.
    Slamon D et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177PubMedCrossRefGoogle Scholar
  157. 157.
    Slansky J et al (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCRcomplex. Immunity 13:529PubMedCrossRefGoogle Scholar
  158. 158.
    Smorlesi A et al (2006) Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24:1766–1775PubMedCrossRefGoogle Scholar
  159. 159.
    Spaner D et al (2006) Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 106:890–899PubMedCrossRefGoogle Scholar
  160. 160.
    Sprent J (1995) Central tolerance of T cells. Int Rev Immunol 13:95–105PubMedCrossRefGoogle Scholar
  161. 161.
    Starr T, Jameson S, Hogquist K (2003) Positive and negative selection of T cells. Annu Rev Immunol 21:139–176PubMedCrossRefGoogle Scholar
  162. 162.
    Steller M (2003) Human papillomavirus, it’s genes em leader and cancer vaccines. Cancer Cell 3:7PubMedCrossRefGoogle Scholar
  163. 163.
    Surh C, Sprent J (1994) T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372:100–103PubMedCrossRefGoogle Scholar
  164. 164.
    Takahashi C, Mittler R, Vella A (1999) Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 162:5037PubMedGoogle Scholar
  165. 165.
    Takeda K, Akira S (2003) Toll receptors and pathogen resistance. Cell Microbiol 5:143–153PubMedCrossRefGoogle Scholar
  166. 166.
    Tan T, Coussens L (2007) Humoral immunity, inflammation and cancer. Curr Opin Immunol 19(2):209–216PubMedCrossRefGoogle Scholar
  167. 167.
    Tangri S et al (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194:833PubMedCrossRefGoogle Scholar
  168. 168.
    Taraban V et al (2002) Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 32:3617PubMedCrossRefGoogle Scholar
  169. 169.
    Tegerstedt K et al (2005) A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 65:5953–5957PubMedCrossRefGoogle Scholar
  170. 170.
    Teramoto K et al (2007) Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA. Cancer Immunol Immunother 56:331–342PubMedCrossRefGoogle Scholar
  171. 171.
    Thomas A, June C (2001) The promise of T-lymphocyte immunotherapy for the treatment of malignant disease. Cancer J 7(Suppl 2):S67–S75PubMedGoogle Scholar
  172. 172.
    Timmerman J et al (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62:5845–5852PubMedGoogle Scholar
  173. 173.
    Tormo D et al (2006) Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 66:5427–5435PubMedCrossRefGoogle Scholar
  174. 174.
    Treurniet H et al (1992) Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor. Cancer Res 52:2344PubMedGoogle Scholar
  175. 175.
    Tudor D et al (2005) TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 23:1258–1264PubMedCrossRefGoogle Scholar
  176. 176.
    Valmori D et al (2000) Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 164:1125PubMedGoogle Scholar
  177. 177.
    Valmori D et al (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 104:8947–8952PubMedCrossRefGoogle Scholar
  178. 178.
    Van Den Eynde B, Boon T (1997) Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27:81PubMedCrossRefGoogle Scholar
  179. 179.
    Van Der Bruggen P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643PubMedCrossRefGoogle Scholar
  180. 180.
    Van Der Bruggen P et al (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 includes cytolytic T lymphocytes that recognize tumor cells expressing MAGE- 3. Eur J Immunol 24:3038PubMedCrossRefGoogle Scholar
  181. 181.
    Van Der Geer P, Hunter T, Lindberg R (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10:251–337PubMedCrossRefGoogle Scholar
  182. 182.
    Van Der Merwe P, Davis S (2003) Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 21:659PubMedCrossRefGoogle Scholar
  183. 183.
    Vitiello A et al (1991) Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173:1007PubMedCrossRefGoogle Scholar
  184. 184.
    Vo-Dinh T, Kasili P, Wabuyele M (2006) Nanoprobes and nanobiosensors for monitoring and imaging individual living cells. Nanomedicine 2:22–30PubMedGoogle Scholar
  185. 185.
    Watts T (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68PubMedCrossRefGoogle Scholar
  186. 186.
    Weinberg A (2002) OX40: targeted immunotherapy - implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 23:102PubMedCrossRefGoogle Scholar
  187. 187.
    Wolpoe M et al (2003) HER-2/neu-specific monoclonal antibodies collaborate with HER-2/ neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 171:2161–2169PubMedGoogle Scholar
  188. 188.
    Woo C et al (2006) Recent clinical progress in virus-based therapies for cancer. Expert Opin Biol Ther 6:1123–1134PubMedCrossRefGoogle Scholar
  189. 189.
    Wu K et al (2002) Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 1(9):695–706PubMedGoogle Scholar
  190. 190.
    Yancik R (1997) Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80:1273–1283PubMedCrossRefGoogle Scholar
  191. 191.
    Yang S et al (2005) Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol 175:3715–3723PubMedGoogle Scholar
  192. 192.
    Yee C et al (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162:2227PubMedGoogle Scholar
  193. 193.
    Yu D et al (1998) Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16:2087–2094PubMedCrossRefGoogle Scholar
  194. 194.
    Zaks T, Rosenberg S (1998) Immunization with a peptide epitope (p369–p377) from HER- 2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu +tumors. Cancer Res 58(21):4902–4908PubMedGoogle Scholar
  195. 195.
    Zhai Y et al (1997) Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 20:15PubMedCrossRefGoogle Scholar
  196. 196.
    Zugel U et al (1998) Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues. J Immunol 161:1705PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Joseph Lustgarten
    • 1
  • Noweeda Mirza
    • 1
  1. 1.Cancer Center ScottsdaleMayo Clinic ArizonaScottsdaleUSA

Personalised recommendations